These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 22286140

  • 1. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.
    Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M, Daniel C, Wiesener M, Voll RE, Amann K.
    Nephron Exp Nephrol; 2012; 120(2):e47-58. PubMed ID: 22286140
    [Abstract] [Full Text] [Related]

  • 2. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
    Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE.
    Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
    [Abstract] [Full Text] [Related]

  • 3. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.
    Lee SW, Kim BS.
    Clin Exp Rheumatol; 2010 Jul; 28(3):393-6. PubMed ID: 20497633
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib treatment prevents glomerulosclerosis associated with lupus nephritis in a murine model through suppressive effects on the immune and renin-angiotensin systems.
    Matsuki-Muramoto Y, Nozawa K, Uomori K, Sekigawa I, Takasaki Y.
    Mod Rheumatol; 2017 Jan; 27(1):77-86. PubMed ID: 27166507
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.
    Lui SL, Yung S, Tsang R, Zhang F, Chan KW, Tam S, Chan TM.
    Lupus; 2008 Apr; 17(4):305-13. PubMed ID: 18413412
    [Abstract] [Full Text] [Related]

  • 6. Development of lupus nephritis is associated with qualitative changes in the glomerular collagen IV matrix composition.
    Tveita AA, Ninomiya Y, Sado Y, Rekvig OP, Zykova SN.
    Lupus; 2009 Apr; 18(4):355-60. PubMed ID: 19276304
    [Abstract] [Full Text] [Related]

  • 7. Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings.
    Gatto M, Radu CM, Luisetto R, Ghirardello A, Bonsembiante F, Trez D, Valentino S, Bottazzi B, Simioni P, Cavicchioli L, Doria A.
    J Autoimmun; 2020 Jul; 111():102443. PubMed ID: 32265078
    [Abstract] [Full Text] [Related]

  • 8. Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.
    Ko K, Wang J, Perper S, Jiang Y, Yanez D, Kaverina N, Ai J, Liarski VM, Chang A, Peng Y, Lan L, Westmoreland S, Olson L, Giger ML, Chun Wang L, Clark MR.
    Arthritis Rheumatol; 2016 Nov; 68(11):2740-2751. PubMed ID: 27159593
    [Abstract] [Full Text] [Related]

  • 9. Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis.
    Mjelle JE, Rekvig OP, Fenton KA.
    Ann Rheum Dis; 2007 Dec; 66(12):1661-8. PubMed ID: 17504842
    [Abstract] [Full Text] [Related]

  • 10. Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.
    Horvei KD, Pedersen HL, Fismen S, Thiyagarajan D, Schneider A, Rekvig OP, Winkler TH, Seredkina N.
    PLoS One; 2017 Dec; 12(11):e0188863. PubMed ID: 29190833
    [Abstract] [Full Text] [Related]

  • 11. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
    Huber JM, Tagwerker A, Heininger D, Mayer G, Rosenkranz AR, Eller K.
    Am J Physiol Renal Physiol; 2009 Aug; 297(2):F451-60. PubMed ID: 19458122
    [Abstract] [Full Text] [Related]

  • 12. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis.
    Kalaaji M, Sturfelt G, Mjelle JE, Nossent H, Rekvig OP.
    Arthritis Rheum; 2006 Mar; 54(3):914-26. PubMed ID: 16508974
    [Abstract] [Full Text] [Related]

  • 13. Histopathology of lupus-like nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice.
    Jacob M, Napirei M, Ricken A, Dixkens C, Mannherz HG.
    Lupus; 2002 Mar; 11(8):514-27. PubMed ID: 12220106
    [Abstract] [Full Text] [Related]

  • 14. Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
    Rudofsky UH, Evans BD, Balaban SL, Mottironi VD, Gabrielsen AE.
    Lab Invest; 1993 Apr; 68(4):419-26. PubMed ID: 8479150
    [Abstract] [Full Text] [Related]

  • 15. Glomerular Proteomic Profiles in the NZB/W F1 Hybrid Mouse Model of Lupus Nephritis.
    Xue L, Shuyan T, Xiaoli L, Zilong L, Qiuling F, Lining W, Yanqiu L, Li Y.
    Med Sci Monit; 2019 Mar 22; 25():2122-2131. PubMed ID: 30900683
    [Abstract] [Full Text] [Related]

  • 16. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA.
    Int Immunopharmacol; 2012 Jan 22; 12(1):257-70. PubMed ID: 22178195
    [Abstract] [Full Text] [Related]

  • 17. A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy.
    Bonaud A, Bender S, Touchard G, Lacombe C, Srour N, Delpy L, Oblet C, Druilhe A, Quellard N, Javaugue V, Cogné M, Bridoux F, Sirac C.
    Blood; 2015 Aug 06; 126(6):757-65. PubMed ID: 26113545
    [Abstract] [Full Text] [Related]

  • 18. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus.
    Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, Galanaud P, Peuchmaur M, Emilie D.
    J Immunol; 2003 Mar 15; 170(6):3392-400. PubMed ID: 12626600
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.
    Ikeda T, Fujii H, Nose M, Kamogawa Y, Shirai T, Shirota Y, Ishii T, Harigae H.
    Arthritis Res Ther; 2017 Aug 11; 19(1):187. PubMed ID: 28800777
    [Abstract] [Full Text] [Related]

  • 20. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus.
    Liao TD, Nakagawa P, Janic B, D'Ambrosio M, Worou ME, Peterson EL, Rhaleb NE, Yang XP, Carretero OA.
    Am J Physiol Renal Physiol; 2015 May 15; 308(10):F1146-54. PubMed ID: 25740596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.